These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 34452655)

  • 1. Specific Prescribing Information for Geriatric Use in the 2019 Product Labeling for Novel New Drug Approvals.
    Lisi DM
    Sr Care Pharm; 2021 Sep; 36(9):455-465. PubMed ID: 34452655
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessment of geriatric information on the drug label for commonly prescribed drugs in older people.
    Steinmetz KL; Coley KC; Pollock BG
    J Am Geriatr Soc; 2005 May; 53(5):891-4. PubMed ID: 15877571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of FDA Amendments Act Section 921 Experience in Posting Data-mining Results from the FAERS Database.
    Beninger P; Murray M
    Clin Ther; 2021 Feb; 43(2):380-395. PubMed ID: 33504449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety-Related Postmarketing Modifications of Drugs for Hematological Malignancies.
    Gafter-Gvili A; Tibau A; Raanani P; Shepshelovich D
    Acta Haematol; 2020; 143(1):73-77. PubMed ID: 31167178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sources of Evidence Triggering and Supporting Safety-Related Labeling Changes: A 10-Year Longitudinal Assessment of 22 New Molecular Entities Approved in 2008 by the US Food and Drug Administration.
    Croteau D; Pinnow E; Wu E; Muñoz M; Bulatao I; Dal Pan G
    Drug Saf; 2022 Feb; 45(2):169-180. PubMed ID: 35113347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inclusion of Older People Reflective of Real-World Clinical Practice in Cardiovascular Drug Trials.
    Caughey GE; Inacio MC; Bell JS; Vitry AI; Shakib S
    J Am Heart Assoc; 2020 Nov; 9(21):e016936. PubMed ID: 33103558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials.
    Shepshelovich D; Tibau A; Goldvaser H; Ocana A; Seruga B; Amir E
    Mayo Clin Proc; 2019 Jan; 94(1):74-83. PubMed ID: 30611457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials.
    Shepshelovich D; Tibau A; Goldvaser H; Molto C; Ocana A; Seruga B; Amir E
    J Clin Oncol; 2018 Jun; 36(18):1798-1804. PubMed ID: 29641296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs.
    Kim J; Nair A; Keegan P; Beaver JA; Kluetz PG; Pazdur R; Chuk M; Blumenthal GM
    Oncologist; 2020 Apr; 25(4):348-354. PubMed ID: 32297444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A year in review: new drugs for older adults in 2011.
    Vande Griend JP; Marcum ZA; Linnebur SA
    Am J Geriatr Pharmacother; 2012 Aug; 10(4):258-63. PubMed ID: 22682643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Information for adequate prescribing to older patients : an evaluation of the product information of 53 recently approved medicines.
    Beers E; Egberts TC; Leufkens HG; Jansen PA
    Drugs Aging; 2013 Apr; 30(4):255-62. PubMed ID: 23420118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International Coherence of Pediatric Drug Labeling for Drug Safety: Comparison of Approved Labels in Korea and the United States.
    Song YK; Han N; Burckart GJ; Oh JM
    Clin Pharmacol Ther; 2020 Mar; 107(3):530-540. PubMed ID: 31544241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in pregnancy labeling and data quality for US-approved pharmaceuticals.
    Mazer-Amirshahi M; Samiee-Zafarghandy S; Gray G; van den Anker JN
    Am J Obstet Gynecol; 2014 Dec; 211(6):690.e1-11. PubMed ID: 24912093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outdated Prescription Drug Labeling: How FDA-Approved Prescribing Information Lags Behind Real-World Clinical Practice.
    Shea MB; Stewart M; Van Dyke H; Ostermann L; Allen J; Sigal E
    Ther Innov Regul Sci; 2018 Nov; 52(6):771-777. PubMed ID: 29714570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Introduction to the new prescription drug labeling by the Food and Drug Administration.
    Lal R; Kremzner M
    Am J Health Syst Pharm; 2007 Dec; 64(23):2488-94. PubMed ID: 18029957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not.
    Citrome L; Nasrallah HA
    Expert Opin Pharmacother; 2012 Aug; 13(11):1599-613. PubMed ID: 22017361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act.
    Hwang TJ; Orenstein L; Kesselheim AS; Bourgeois FT
    JAMA Pediatr; 2019 Jan; 173(1):68-74. PubMed ID: 30452498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mining FDA drug labels using an unsupervised learning technique--topic modeling.
    Bisgin H; Liu Z; Fang H; Xu X; Tong W
    BMC Bioinformatics; 2011 Oct; 12 Suppl 10(Suppl 10):S11. PubMed ID: 22166012
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.